Clinical Trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Study acronym: TARGET-D 202
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-31
notable Trial sites expanded: 0 -> 3 locations 2026-07-14
Trial Details
NCT Number NCT07659782
Lead Sponsor Verastem, Inc.
Conditions Non-Small Cell Lung Cancer
Enrollment 105 participants
Start Date 2026-07-22
Primary Completion 2027-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-11